100 Participants Needed

Vabysmo for Diabetic Retinopathy

Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Colorado, Denver
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are using any ocular anti-VEGF treatments, you must stop them at least 3 months before starting the trial.

What data supports the effectiveness of the drug Vabysmo (Faricimab) for treating diabetic retinopathy?

Research shows that Faricimab, marketed as Vabysmo, has been effective in improving vision and reducing retinal thickness in patients with diabetic macular edema, a condition related to diabetic retinopathy. In clinical trials, Faricimab demonstrated similar or better results compared to other treatments, with fewer injections needed, indicating its potential effectiveness for diabetic retinopathy.12345

Is Vabysmo (Faricimab) safe for humans?

Vabysmo (Faricimab) has been studied in several clinical trials for conditions like diabetic macular edema and neovascular age-related macular degeneration, showing a good safety profile. These studies indicate that it is generally safe for human use, with safety data supporting its approval in the USA and Japan.12367

What makes the drug Vabysmo unique for treating diabetic retinopathy?

Vabysmo (faricimab) is unique because it is a bispecific antibody that targets two key factors involved in eye disease: VEGF-A and Ang-2, potentially allowing for longer intervals between injections and reducing treatment burden compared to traditional therapies.12389

What is the purpose of this trial?

In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting complications from pars plana vitrectomy for diabetic vitreous hemorrhage with or without tractional retinal detachments.

Eligibility Criteria

This trial is for adults over 18 with non-clearing vitreous hemorrhage due to diabetic retinopathy, who are undergoing eye surgery. They must be able to follow the study plan and use effective contraception if of childbearing potential. Those unable to commit or at risk of not complying with contraceptive guidelines are excluded.

Inclusion Criteria

I have a severe eye condition due to diabetes and need surgery.

Exclusion Criteria

General exclusion criteria: Known hypersensitivity to components in the faricimab injection, dilating eye drops, disinfectants, anesthetics, or antimicrobial preparations used during the study, History of diseases or conditions contraindicating the use of faricimab, Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab. Women of childbearing potential must have negative pregnancy tests at specified time points.
My study eye has not had recent treatments or surgeries, and only has diabetic retinopathy.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive peri-operative faricimab or sham injection to evaluate efficacy in limiting complications from pars plana vitrectomy

6 months
Intra-operative and post-operative visits

Follow-up

Participants are monitored for safety and effectiveness after treatment, including BCVA outcomes and rates of post-operative complications

12 months
Regular follow-up visits

Treatment Details

Interventions

  • Faricimab
Trial Overview The study tests whether Vabysmo (Faricimab) injections before eye surgery can reduce complications compared to a sham treatment in patients with diabetic-related bleeding in the eye. Participants will be randomly assigned to receive either the real drug or a placebo.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Faricimab injectionExperimental Treatment1 Intervention
Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The 6-mg dose of faricimab will be administered by IVT at the study site to patients. A specified filter needle must be used for each dose preparation of faricimab according to the instructions provided in the Investigator's Brochure and package insert. No other material than specified should be used. Vials of faricimab drug product are for a single-dose only (one injection preparation per patient per eye). Vials used for one patient must not be used for any other patient. Partially used vials, remaining faricimab drug product, as well as administration material must not be reused.
Group II: Sham injectionPlacebo Group1 Intervention
Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The sham procedure mimics an intravitreal injection of faricimab except that the blunt end of an empty syringe is pressed against an anesthetized eye instead of a needle attached to a faricimab-filled syringe.

Faricimab is already approved in United States, European Union, Canada for the following indications:

πŸ‡ΊπŸ‡Έ
Approved in United States as Vabysmo for:
  • Neovascular age-related macular degeneration (nAMD)
  • Diabetic macular edema (DME)
  • Macular edema following retinal vein occlusion (RVO)
πŸ‡ͺπŸ‡Ί
Approved in European Union as Vabysmo for:
  • Neovascular age-related macular degeneration (nAMD)
  • Diabetic macular edema (DME)
πŸ‡¨πŸ‡¦
Approved in Canada as Vabysmo for:
  • Neovascular age-related macular degeneration (nAMD)
  • Diabetic macular edema (DME)

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+

Findings from Research

Faricimab, a dual-target antibody for VEGF-A and Ang-2, has shown comparable efficacy to monthly ranibizumab in treating neovascular age-related macular degeneration, allowing for longer intervals between injections and fewer treatments overall.
In the BOULEVARD trial, faricimab significantly improved diabetic retinopathy severity in 38.6% of patients treated with the highest dose, outperforming ranibizumab, indicating its potential for effective long-term management of diabetic macular edema.
[Faricimab: from research to clinical practice].Yusef, YN., Budzinskaya, MV., Plyukhova, AA.[2023]
The phase III BALATON/COMINO trials will assess the efficacy and safety of faricimab in treating diabetic macular edema due to retinal vein occlusion, involving 1282 patients across 22 countries.
Faricimab is being compared to aflibercept using a personalized treatment approach that adjusts dosing intervals based on individual patient responses, aiming to demonstrate noninferiority in visual acuity outcomes.
BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale.Hattenbach, LO., Abreu, F., Arrisi, P., et al.[2023]
Faricimab is a bispecific antibody that targets both VEGF-A and Ang-2, and it has been approved in the USA for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
The drug is administered via intravitreal injection and is currently undergoing Phase III clinical trials for additional retinal vascular diseases, indicating its potential for broader therapeutic applications.
Faricimab: First Approval.Shirley, M.[2022]

References

1.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Faricimab: from research to clinical practice]. [2023]
BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. [2023]
Faricimab: First Approval. [2022]
Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration. [2023]
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. [2020]
Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials. [2023]
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. [2023]
Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. [2023]
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security